PATENT CLAIM ANALYSIS

Application Number: 15771043
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-02
Patent Classification: ["514", "021300"]

Abstract:
The present invention includes methods of improving proteolytic stability of a polypeptide, comprising alkylating at least one selected from the group consisting of a N-terminus amino group, the NH group of the N-terminus first internal amide bond, another primary amino group, a thiol group and a thioether group within the polypeptide. The present invention further includes polypeptides incorporating such chemical modifications.

Claim (Index 22):
The chemically modified polypeptide of  claim 1 , wherein the polypeptide is selected from the group consisting of:\n GLP-1 (H*AEGTFTS*DVS*S*YLEGQAAK*EFIAWLVK*GR); Exenatide (H*GEGT*FT*S*DLS*KQM*EEEAVRLFIEWLK*NGGPS*S*GAPPPS*-NH 2 ); Liraglutide (H*AEGT*FT*S*DVS*S*Y*LEGQAA-(N 6 -Palmitoylglutamyl)K*EFIAWLVRGRG); Semaglutide (H*AibEGT*FT*S*DVS*S*Y*LEGQAA-(X)K*EFIAWLVRGRG), wherein X\n attached to the \u03b5-amino group of lysine is: \n Taspoglutide (H*AibEGT*FT*S*DVS*S*YLEGQAAK*EFIAWLVK*AibR-NH 2 ); Lixisenatide (H*GEGT*FT*S*DLS*K*QM*EEEAVRLFIEWLK*NGGPS*S*GAPPS*K*K*K*K*K* K*-NH 2 ); Triagonist (H*AibQGT*FT*S*D-(\u03b3-E-C 16  acyl)KS*K*YLDERAAQDFVQWLLDGGPS*S*GAPPPS*-NH 2 ); Exendin (H*GEGTFTS*DLS*KQMEEEAVRLFIEWLK*NGGPS*S*GAPPPS); VIP (H*S*DAVFTDNYTRLRK*QMAVK*K*YLNS*ILN); PACAP (H*S*DGIFTDS*YS*RYRK*QMAVK*K*YLAAVLGK*RYKQRVK*NK*); GIP (Y*AEGTFIS*DYS*IAMDK*IHQQDFVNWLLAQK*GK*K*NDWK*HNITQ); Met-Enkephalin (Y*GGFM); BNP (Y*PSKPDNPGEDAPAEDMARYYS*ALRHYINLITRQRY); Substance P (R*PK*PQQFFGLM); Tyr-MIF-1 (Y*LG); Tyr-W-MIF-1 (Y*PWG); glucagon (H*SQGTFTSDYSKYLDSRRAQDFVQWLMNT); Growth Hormone Releasing Hormone (GHRH); Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) ADCYAP1; Glucagon (GCG); Gastric Inhibitory Polypeptide (GIP); Secretin (SCT); Vasoactive Intestinal Peptid (VIP); OXM (oxyntomodulin); PTH (Parathyroid hormone); Peptide YY3-36 and Peptide YY1-36 (PYY); NPY (Neuropeptide Y); VIP peptide (Vasoactive intestinal peptide); Dual agonists for at least one selected from the group consisting of GLP-1+GIP; GLP-1+amylin; GLP-1+gastrin; GLP-1+estrogen; GLP-1+PYY, GLP-1+cholecystin kinase (CCK); Dual agonists for GLP-1R+glucagon receptor; Mixed agonists; Albiglutide; Dulaglutide; Other GLP-1R agonists; Amylin; Other substrates of DPP4, DPP2 and/or a protease with \u226550% homology to DPP4 and/or DPP2; GLP-1 analogues stabilized by other modifications; or a sequence with at least 75% identity to any of these sequences, wherein at least one of the residues marked with * is alkylated or acylated with R.

Metadata:
- Claim Count in Document: 39.0
- Percentile: 91.0
- Lexical Diversity: 1.59524
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12845455', '13130962', '14182706', '13697021', '12066324']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7938883732374032
- 35 USC 102 Novelty (BERT): 0.5062591028316518
- Combined Prediction Score: 0.7651254461968281
- Mean Citation Score: 258.376928
- Max Citation Score: 264.86304
- Similarity Product: 182.33147212486267

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test